search
Back to results

The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
North American Ginseng (Panax Quinquefolius)
Sponsored by
Risk Factor Modification Centre
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Blood Pressure, Ambulatory Blood Pressure Monitoring, Complementary and Alternative Medicine, Herbal, North American Ginseng, Panax Quinquefolius

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: aged 18 to 85 years hypertension as defined by the use of antihypertensive drugs or a seated systolic blood pressure greater than or equal to 140 mm Hg or a diastolic BP greater than or equal to 90 mm Hg at each of 3 pre-study visits. Exclusion Criteria: secondary hypertension diabetes kidney liver disease unstable angina ginseng use for two months prior to or during the study any changes in the type or dose of antihypertensive drugs one month prior to or during the study

Sites / Locations

  • Risk Factor Modification Centre, St. Michael's Hospital

Outcomes

Primary Outcome Measures

Mean 24 Hour Ambulatory Blood Pressure

Secondary Outcome Measures

Mean Daytime Ambulatory Blood Pressure
Mean Nighttime Ambulatory Blood Pressure
Cystatin C

Full Information

First Posted
September 14, 2005
Last Updated
September 14, 2005
Sponsor
Risk Factor Modification Centre
Collaborators
Ontario Ministry of Agriculture, Food and Rural Affairs, Ontario Ginseng Growers Association
search

1. Study Identification

Unique Protocol Identification Number
NCT00219960
Brief Title
The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension
Official Title
The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
June 2004
Overall Recruitment Status
Completed
Study Start Date
April 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2003 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Risk Factor Modification Centre
Collaborators
Ontario Ministry of Agriculture, Food and Rural Affairs, Ontario Ginseng Growers Association

4. Oversight

5. Study Description

Brief Summary
To determine the effect of North American ginseng on blood pressure in individuals with hypertension.
Detailed Description
Ginseng lacks proper clinical scrutiny for its effect on blood pressure (BP), in spite of observational evidence linking its intake to hypertension. This should be addressed considering the potential overlap between the prevalence of ginseng use and hypertension. We undertook a single centre, randomized, controlled, double-blinded, crossover trial to determine the effect of North American ginseng (NAG) on 24-hour BP and renal function. After a 4-week placebo run-in, we randomly assigned participants to NAG or placebo treatment for 12-weeks at a dose of 3g/day. This was followed by an 8-week washout, and a subsequent 12-week period in which the opposite treatment was consumed. At run-in, and at weeks 0 and 12 of each treatment period, participants were fitted with an ambulatory BP monitor to assess 24-hour BP and serum cystatin C was measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Blood Pressure, Ambulatory Blood Pressure Monitoring, Complementary and Alternative Medicine, Herbal, North American Ginseng, Panax Quinquefolius

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
52 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
North American Ginseng (Panax Quinquefolius)
Primary Outcome Measure Information:
Title
Mean 24 Hour Ambulatory Blood Pressure
Secondary Outcome Measure Information:
Title
Mean Daytime Ambulatory Blood Pressure
Title
Mean Nighttime Ambulatory Blood Pressure
Title
Cystatin C

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: aged 18 to 85 years hypertension as defined by the use of antihypertensive drugs or a seated systolic blood pressure greater than or equal to 140 mm Hg or a diastolic BP greater than or equal to 90 mm Hg at each of 3 pre-study visits. Exclusion Criteria: secondary hypertension diabetes kidney liver disease unstable angina ginseng use for two months prior to or during the study any changes in the type or dose of antihypertensive drugs one month prior to or during the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vladimir Vuksan, PhD
Organizational Affiliation
Risk Factor Modification Centre, St. Michael's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Risk Factor Modification Centre, St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5C 2T2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension

We'll reach out to this number within 24 hrs